Inspired by this, we also explored the potential predictive value of p53, p63, and EGFR status for neoadjuvant therapy efficacy, as well as the potential of p53, p63, and EGFR mutations as new therapeutic targets for breast cancer. Here, TP63 is linked to breast carcinoma.